Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03419650 · ClinicalTrials.gov registry record · Phase 4
Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)
A Phase 4 study, sponsored by IRIS Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT03419650 is a Phase 4 study that has completed, run by IRIS Research and Development. The registered enrollment target is 10 participants.
The verdict
NCT03419650, a Phase 4 study, has completed, sponsored by IRIS Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.
Interventions
- DRUG ACTHar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-07-20 |
| Est. Completion | 2021-08-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03419650
The ClinicalTrials.gov registry entry for NCT03419650 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IRIS Research and Development, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACTHar is the first listed.
NCT03419650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03419650 about?
NCT03419650 is a clinical study titled "Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)". Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.
What is the current status of trial NCT03419650?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2018-07-20. Estimated completion is 2021-08-25.
What interventions are being tested in trial NCT03419650?
The interventions under investigation include: ACTHar (DRUG).
Who is sponsoring clinical trial NCT03419650?
This trial is sponsored by IRIS Research and Development, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.